New drug targets Hard-to-Treat colorectal cancer in early trial
NCT ID NCT07106892
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called HLX43 in 60 people with advanced colorectal cancer that has stopped responding to standard treatments. The drug is designed to attach to a protein on cancer cells and deliver a toxin to kill them. The main goal is to find the right dose and see how well it shrinks tumors, while also checking for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
-
Jinan First People's Hospital
RECRUITINGJinan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Why are more younger adults getting colorectal cancer? a national study digs into the data
- New drug combo aims to boost response in Hard-to-Treat colorectal cancer
- First-in-Class cancer drug targets Hard-to-Treat tumors
- New pill targets Hard-to-Treat cancers with a specific gene mutation
- AI eye on cancer: robot helps spot hidden polyps
- New hope for Hard-to-Treat colorectal cancer? drug combo trial launches